The present invention relates to a group of compounds with an acylhydrazone structural core having the capacity to modulate interaction between NCS-1 and Ric8a proteins involved in the process of regulating the number of synapses and the neurotransmitter release probability. These compounds are therefore useful for the treatment of neurological diseases in which the number of synapses is affected, such as Alzheimer's disease, Huntington's disease, or Parkinson's disease.
本发明涉及一组具有酰基腙结构核心的化合物,具有调节参与调节突触数量和神经递质释放概率过程中的
NCS-1和Ric8a蛋白相互作用的能力。因此,这些化合物对于治疗突触数量受影响的神经系统疾病,如阿尔茨海默病、亨廷顿病或帕
金森病,是有用的。